DSG3 and acquired polycythemia vera: Factors that have been identified to predict better treatment response in PV include falls in both anti-Dsg1 and -Dsg3 antibodies (7–9), shorter disease duration (10), and higher baseline CD4 T cell counts prior to rituximab treatment (7).